Royal Bank of Canada reiterated their buy rating on shares of Flexion Therapeutics (NASDAQ:FLXN) in a research note published on Sunday morning, AnalystRatings.com reports.
Several other equities analysts have also recently commented on the stock. HC Wainwright reissued a buy rating on shares of Flexion Therapeutics in a research report on Wednesday, April 14th. Raymond James lowered their target price on Flexion Therapeutics from $18.00 to $16.00 and set a strong-buy rating for the company in a research note on Wednesday, April 14th. Zacks Investment Research raised Flexion Therapeutics from a sell rating to a hold rating in a research report on Tuesday, March 16th. Wells Fargo & Company decreased their price objective on Flexion Therapeutics from $16.00 to $15.00 and set an overweight rating for the company in a research note on Wednesday, January 27th. Finally, Credit Suisse Group cut their target price on shares of Flexion Therapeutics from $18.00 to $17.00 and set an outperform rating on the stock in a research note on Wednesday, April 14th. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Flexion Therapeutics currently has a consensus rating of Buy and a consensus price target of $19.75.
Shares of Flexion Therapeutics stock opened at $8.61 on Friday. The stock has a market capitalization of $429.85 million, a price-to-earnings ratio of -2.79 and a beta of 1.64. The company has a debt-to-equity ratio of 12.77, a current ratio of 4.66 and a quick ratio of 4.31. The business has a 50-day moving average of $9.91 and a 200 day moving average of $11.30. Flexion Therapeutics has a 12 month low of $7.80 and a 12 month high of $14.39.
In other Flexion Therapeutics news, insider Melissa Layman sold 2,624 shares of the firm’s stock in a transaction that occurred on Thursday, January 28th. The shares were sold at an average price of $12.55, for a total transaction of $32,931.20. Following the sale, the insider now owns 91,000 shares of the company’s stock, valued at $1,142,050. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 17.03% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Eudaimonia Partners LLC acquired a new stake in Flexion Therapeutics during the 3rd quarter worth $36,000. Truist Financial Corp increased its position in shares of Flexion Therapeutics by 11.5% during the fourth quarter. Truist Financial Corp now owns 23,972 shares of the specialty pharmaceutical company’s stock worth $277,000 after purchasing an additional 2,472 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Flexion Therapeutics by 10.4% in the 4th quarter. The Manufacturers Life Insurance Company now owns 27,386 shares of the specialty pharmaceutical company’s stock valued at $316,000 after purchasing an additional 2,591 shares during the last quarter. Snow Capital Management LP boosted its position in shares of Flexion Therapeutics by 1.0% in the 4th quarter. Snow Capital Management LP now owns 306,265 shares of the specialty pharmaceutical company’s stock valued at $3,534,000 after purchasing an additional 3,000 shares during the period. Finally, Prelude Capital Management LLC grew its stake in Flexion Therapeutics by 13.1% during the 4th quarter. Prelude Capital Management LLC now owns 31,000 shares of the specialty pharmaceutical company’s stock worth $358,000 after buying an additional 3,600 shares during the last quarter.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.
Recommended Story: Pattern Day Trader – What is the PDT Rule?
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.